PL3335724T3 - Pojedyncze domeny zmienne immunoglobuliny do zastosowania w sposobach leczenia TTP - Google Patents
Pojedyncze domeny zmienne immunoglobuliny do zastosowania w sposobach leczenia TTPInfo
- Publication number
- PL3335724T3 PL3335724T3 PL18153674.9T PL18153674T PL3335724T3 PL 3335724 T3 PL3335724 T3 PL 3335724T3 PL 18153674 T PL18153674 T PL 18153674T PL 3335724 T3 PL3335724 T3 PL 3335724T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- variable domains
- single variable
- immunoglobulin single
- treating ttp
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title 1
- 102000018358 immunoglobulin Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2013007A NL2013007B1 (en) | 2014-06-16 | 2014-06-16 | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
| US201462030817P | 2014-07-30 | 2014-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3335724T3 true PL3335724T3 (pl) | 2022-09-19 |
Family
ID=51541255
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18153671T PL3366305T3 (pl) | 2014-06-16 | 2015-06-16 | Sposoby leczenia ttp za pomocą pojedyńczych immunoglobulinowych domen zmiennych i ich zastosowania |
| PL15729829T PL3154569T3 (pl) | 2014-06-16 | 2015-06-16 | Pojedyncze domeny zmienne immunoglobuliny do zastosowania w leczeniu TTP |
| PL18153676T PL3332800T3 (pl) | 2014-06-16 | 2015-06-16 | Pojedyncze domeny zmienne immunoglobuliny do stosowania w sposobach leczenia TTP |
| PL18153673.1T PL3335723T3 (pl) | 2014-06-16 | 2015-06-16 | Pojedyncze domeny zmienne immunoglobuliny do zastosowania w sposobach leczenia TTP |
| PL18153674.9T PL3335724T3 (pl) | 2014-06-16 | 2015-06-16 | Pojedyncze domeny zmienne immunoglobuliny do zastosowania w sposobach leczenia TTP |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18153671T PL3366305T3 (pl) | 2014-06-16 | 2015-06-16 | Sposoby leczenia ttp za pomocą pojedyńczych immunoglobulinowych domen zmiennych i ich zastosowania |
| PL15729829T PL3154569T3 (pl) | 2014-06-16 | 2015-06-16 | Pojedyncze domeny zmienne immunoglobuliny do zastosowania w leczeniu TTP |
| PL18153676T PL3332800T3 (pl) | 2014-06-16 | 2015-06-16 | Pojedyncze domeny zmienne immunoglobuliny do stosowania w sposobach leczenia TTP |
| PL18153673.1T PL3335723T3 (pl) | 2014-06-16 | 2015-06-16 | Pojedyncze domeny zmienne immunoglobuliny do zastosowania w sposobach leczenia TTP |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US10858445B2 (pl) |
| EP (6) | EP3366305B1 (pl) |
| JP (3) | JP6688746B2 (pl) |
| KR (2) | KR102403388B1 (pl) |
| CN (1) | CN106559985A (pl) |
| AU (2) | AU2015276237B2 (pl) |
| CA (1) | CA2952103A1 (pl) |
| ES (5) | ES2843642T3 (pl) |
| IL (1) | IL249540B (pl) |
| NL (1) | NL2013007B1 (pl) |
| PL (5) | PL3366305T3 (pl) |
| PT (5) | PT3154569T (pl) |
| RU (1) | RU2704444C2 (pl) |
| SG (2) | SG10201811109PA (pl) |
| WO (1) | WO2015193326A1 (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL2013007B1 (en) | 2014-06-16 | 2016-07-05 | Ablynx Nv | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
| CN107340225B (zh) * | 2017-07-13 | 2019-07-05 | 徐州医科大学 | 一种基于流式细胞术检测血小板受体GPIba胞外段酶切的方法 |
| MX2020008294A (es) | 2018-02-06 | 2020-11-18 | Ablynx Nv | Metodos de tratamiento de episodio inicial de ttp con dominios variables simples de inmunoglobulina. |
| IL302984A (en) * | 2020-11-18 | 2023-07-01 | Green Cross Corp | Adamts13 variant having increased escaping rate or activity against autoantibody |
| WO2023044272A1 (en) | 2021-09-17 | 2023-03-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies |
| US20240409666A1 (en) * | 2021-12-10 | 2024-12-12 | Renhao Li | Polypeptides That Bind to von Willebrand Factor (VWF) A1 Domain or an Autoinhibitory Module, Variants, and Uses Thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB335768A (en) | 1929-10-24 | 1930-10-02 | Jacoviac Maurice | Improvements in protecting devices for gramophone disc records |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5043429B1 (en) | 1987-05-01 | 1997-10-14 | Scripps Research Inst | Protein fragments containing factor VIII binding domain of von willebrand factor |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| ATE427968T1 (de) | 1992-08-21 | 2009-04-15 | Univ Bruxelles | Immunoglobuline ohne leichtkette |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
| WO2000046383A2 (en) | 1999-02-05 | 2000-08-10 | Rijksuniversiteit Leiden | Method of modulating metabolite biosynthesis in recombinant cells |
| WO2001009300A2 (en) | 1999-08-02 | 2001-02-08 | Keygene N.V. | Method for generating cgmmv resistant plants, genetic constructs, and obtained cgmmv-resistant plants |
| US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| AU2003251238A1 (en) | 2002-08-07 | 2004-02-25 | Umc Utrecht Holding B.V. | Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha |
| BRPI0315666B8 (pt) | 2002-10-23 | 2021-05-25 | Ludwig Inst For Cancer Res Ltd | dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos |
| JP2006517789A (ja) | 2003-01-10 | 2006-08-03 | アブリンクス エン．ヴェー． | 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用 |
| RU2524129C2 (ru) | 2003-01-10 | 2014-07-27 | Аблинкс Н.В. | Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами |
| US7461263B2 (en) | 2003-01-23 | 2008-12-02 | Unspam, Llc. | Method and apparatus for a non-revealing do-not-contact list system |
| AU2003264053A1 (en) | 2003-08-12 | 2005-03-10 | William M. Yarbrough | Treatment for acne vulgaris and method of use |
| US7270976B2 (en) * | 2004-07-19 | 2007-09-18 | American Diagnostica, Inc. | Methods for measuring ADAMTS13 activity and protein on platelets and in plasma |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| US20080107601A1 (en) | 2004-10-13 | 2008-05-08 | Ablynx N.V. | Nanobodies Tm Against Amyloid-Beta and Polypeptides Comprising the Same for the Treatment of Degenerative Neural Diseases Such as Alzheimer's Disease |
| JP4829897B2 (ja) | 2005-01-14 | 2011-12-07 | アブリンクス ナームローゼ フェンノートシャップ | 血小板減少及び／又はフォンビルブラント因子（ｖＷＦ）と血小板との間の自発的相互作用によって特徴づけられる疾患及び障害の異なる形態を区別する方法及びアッセイ |
| PL2444424T3 (pl) * | 2005-05-20 | 2019-01-31 | Ablynx N.V. | Ulepszone Nanociała TM do leczenia zaburzeń, w których pośredniczy agregacja |
| US8629244B2 (en) | 2006-08-18 | 2014-01-14 | Ablynx N.V. | Interleukin-6 receptor binding polypeptides |
| AU2008219216A1 (en) | 2007-02-21 | 2008-08-28 | Ablynx N.V. | Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization |
| NZ581097A (en) | 2007-05-24 | 2012-03-30 | Ablynx Nv | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
| CA2718081A1 (en) | 2008-03-21 | 2009-09-24 | Ablynx Nv | Von willebrand factor specific binders and methods of use therefor |
| WO2010056550A1 (en) | 2008-10-29 | 2010-05-20 | Wyeth Llc | Methods for purification of single domain antigen binding molecules |
| KR101593285B1 (ko) | 2008-10-29 | 2016-02-11 | 아블린쓰 엔.브이. | 단일 도메인 항원 결합 분자의 제형 |
| EP2506874A1 (en) | 2009-12-01 | 2012-10-10 | Ablynx N.V. | Von willebrand factor specific binding agents and uses thereof |
| LT3757126T (lt) * | 2010-11-05 | 2025-12-10 | Novartis Ag | Psoriazinio artrito gydymo būdas, panaudojant il-17 antagonistus |
| DK3412305T3 (da) | 2011-06-10 | 2021-03-01 | Baxalta GmbH | Behandling af koagulationssygdom ved administration af rekombinant vwf |
| MY167125A (en) | 2011-08-17 | 2018-08-13 | Glaxo Group Ltd | Modified proteins and peptides |
| NL2013007B1 (en) | 2014-06-16 | 2016-07-05 | Ablynx Nv | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
| MX2020008294A (es) | 2018-02-06 | 2020-11-18 | Ablynx Nv | Metodos de tratamiento de episodio inicial de ttp con dominios variables simples de inmunoglobulina. |
-
2014
- 2014-06-16 NL NL2013007A patent/NL2013007B1/en active
-
2015
- 2015-06-16 CA CA2952103A patent/CA2952103A1/en not_active Abandoned
- 2015-06-16 PT PT157298290T patent/PT3154569T/pt unknown
- 2015-06-16 EP EP18153671.5A patent/EP3366305B1/en active Active
- 2015-06-16 ES ES18153671T patent/ES2843642T3/es active Active
- 2015-06-16 PT PT181536764T patent/PT3332800T/pt unknown
- 2015-06-16 CN CN201580040020.4A patent/CN106559985A/zh active Pending
- 2015-06-16 ES ES18153673T patent/ES2915473T3/es active Active
- 2015-06-16 PL PL18153671T patent/PL3366305T3/pl unknown
- 2015-06-16 EP EP18153674.9A patent/EP3335724B1/en active Active
- 2015-06-16 AU AU2015276237A patent/AU2015276237B2/en active Active
- 2015-06-16 EP EP18153676.4A patent/EP3332800B1/en active Active
- 2015-06-16 KR KR1020177001152A patent/KR102403388B1/ko active Active
- 2015-06-16 ES ES18153674T patent/ES2924199T3/es active Active
- 2015-06-16 SG SG10201811109PA patent/SG10201811109PA/en unknown
- 2015-06-16 PL PL15729829T patent/PL3154569T3/pl unknown
- 2015-06-16 PL PL18153676T patent/PL3332800T3/pl unknown
- 2015-06-16 SG SG11201610488QA patent/SG11201610488QA/en unknown
- 2015-06-16 PT PT181536749T patent/PT3335724T/pt unknown
- 2015-06-16 EP EP15729829.0A patent/EP3154569B1/en active Active
- 2015-06-16 RU RU2017100077A patent/RU2704444C2/ru active
- 2015-06-16 PL PL18153673.1T patent/PL3335723T3/pl unknown
- 2015-06-16 PL PL18153674.9T patent/PL3335724T3/pl unknown
- 2015-06-16 PT PT181536715T patent/PT3366305T/pt unknown
- 2015-06-16 JP JP2016573549A patent/JP6688746B2/ja active Active
- 2015-06-16 ES ES18153676T patent/ES2831865T3/es active Active
- 2015-06-16 US US15/319,467 patent/US10858445B2/en active Active
- 2015-06-16 PT PT181536731T patent/PT3335723T/pt unknown
- 2015-06-16 EP EP22172948.6A patent/EP4059513A1/en not_active Withdrawn
- 2015-06-16 ES ES15729829T patent/ES2881331T3/es active Active
- 2015-06-16 WO PCT/EP2015/063493 patent/WO2015193326A1/en not_active Ceased
- 2015-06-16 EP EP18153673.1A patent/EP3335723B1/en active Active
- 2015-06-16 KR KR1020227012546A patent/KR102568585B1/ko active Active
-
2016
- 2016-12-13 IL IL249540A patent/IL249540B/en unknown
-
2018
- 2018-01-26 US US15/880,978 patent/US12269893B2/en active Active
- 2018-01-26 US US15/881,055 patent/US20180155443A1/en not_active Abandoned
- 2018-01-26 US US15/880,870 patent/US20180155440A1/en not_active Abandoned
- 2018-01-26 US US15/881,003 patent/US10919980B2/en active Active
-
2020
- 2020-01-30 JP JP2020014229A patent/JP7105260B2/ja active Active
-
2021
- 2021-05-03 AU AU2021202747A patent/AU2021202747B2/en active Active
-
2022
- 2022-07-11 JP JP2022110921A patent/JP2022160431A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281755A (en) | Enhanced variable complexes of immunoglobulins | |
| IL247898A0 (en) | Anti-ox40 antibodies and methods of use | |
| IL252008A0 (en) | Methods for producing bispecific domains, variants of antibodies and their use | |
| IL250724A0 (en) | Methods for treating multiple myeloma with immunomodulatory compounds in combination with antibodies | |
| IL247699A0 (en) | Preparations and methods for the treatment of kidney disorders | |
| PT3335724T (pt) | Domínios variáveis únicos de imunoglobulina para utilização no tratamento da ptt | |
| IL265568A (en) | Methods for treating TIM-3 elevation | |
| HK1236434A1 (en) | Methods of treating ttp with immunoglobulin single variable domains and uses thereof |